ResMed Inc. (RMD) News
Filter RMD News Items
RMD News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
RMD News Highlights
- For RMD, its 30 day story count is now at 17.
- Over the past 18 days, RMD's stories per day has been in a clear downtrend, falling by about 0.46 per 3 days.
- ASX, BAND and GLP are the most mentioned tickers in articles about RMD.
Latest RMD News From Around the Web
Below are the latest news stories about RESMED INC that investors may wish to consider to help them evaluate RMD as an investment opportunity.
Resmed overhauls C-suite, creating 3 posts and parting ways with 2 execsThe company recently laid off 5% of its staff and stopped certain projects to lower operating costs. |
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's WhyKey Insights ResMed's Annual General Meeting to take place on 16th of November Salary of US$1.13m is part of CEO Mick... |
ResMed Adopts New Operating Model to Accelerate Long-term GrowthJustin Leong appointed Chief Product Officer, effective immediately.Katrin Pucknat appointed Chief Marketing Officer, effective immediately.Mike Fliss appointed Chief Revenue Officer, effective immediately.Rob Douglas, President and Chief Operating Officer, to retire January 1, 2024. SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated leadership in Product, Rev |
Why This 1 Growth Stock Could Be a Great Addition to Your PortfolioThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
ResMed Inc's Dividend AnalysisResMed Inc(NYSE:RMD) recently announced a dividend of $0.48 per share, payable on 2023-12-14, with the ex-dividend date set for 2023-11-08. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into ResMed Inc's dividend performance and assess its sustainability. |
2 Monster Stocks to Buy Without Any HesitationFirst, consumer health juggernaut Kenvue (NYSE: KVUE) produces and markets seven No. 1 global brands. Meanwhile, ResMed (NYSE: RMD), a leader in continuous positive airway pressure (CPAP) machines, has delivered enormous total returns of over 24,000% since its initial public offering (IPO) in 1995. Home to seven No. 1 global brands -- Tylenol, Nicorette, Zyrtec, Neutrogena, Listerine, Johnson's, and Band-Aid -- Kenvue operates in 165 countries. |
Be Sure To Check Out ResMed Inc. (NYSE:RMD) Before It Goes Ex-DividendResMed Inc. ( NYSE:RMD ) stock is about to trade ex-dividend in 4 days. Typically, the ex-dividend date is one business... |
Health Care Roundup: Market TalkFind insight on Hypera, Krispy Kreme, Inspecs and more in the latest Market Talks covering the Health Care sector. |
Resmed cuts 5% of staff amid profitability pushThe company has stopped some projects that were not working well as it seeks to cut operating costs, CEO Mick Farrell told investors. |
ResMed Inc. (NYSE:RMD) Q1 2024 Earnings Call TranscriptResMed Inc. (NYSE:RMD) Q1 2024 Earnings Call Transcript October 26, 2023 ResMed Inc. beats earnings expectations. Reported EPS is $1.64, expectations were $1.62. Operator: Hello, and welcome to the ResMed First Quarter Fiscal Year 2024 Earnings Conference Call and Webcast [Operator Instructions]. As a reminder, this conference is being recorded. It’s now my pleasure to […] |